Compare COHU & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | IMCR |
|---|---|---|
| Founded | 1947 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1994 | 2016 |
| Metric | COHU | IMCR |
|---|---|---|
| Price | $38.93 | $31.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $34.00 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 619.8K | 395.0K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,956,000.00 | $249,428,000.00 |
| Revenue This Year | $14.38 | $14.57 |
| Revenue Next Year | $19.12 | $8.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.74 | ★ 43.05 |
| 52 Week Low | $13.66 | $27.47 |
| 52 Week High | $39.24 | $40.71 |
| Indicator | COHU | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 76.48 | 52.33 |
| Support Level | $27.68 | $31.08 |
| Resistance Level | N/A | $31.65 |
| Average True Range (ATR) | 1.61 | 1.15 |
| MACD | 0.80 | 0.20 |
| Stochastic Oscillator | 97.21 | 67.81 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection).
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.